Calidi Biotherapeutics (CLDI)

Executive Summary

Calidi Biotherapeutics is a clinical-stage biotechnology company developing a novel stem cell-based delivery platform (RedTail) for oncolytic viruses and genetic medicines. The platform is designed to protect therapeutic payloads from immune clearance, enabling systemic administration and precise targeting of solid tumors and metastatic disease. Calidi's lead candidate, CLD-401, delivers an IL-15 superagonist directly to the tumor microenvironment to stimulate a potent anti-cancer immune response. The company went public via a reverse merger and is currently advancing CLD-401 through clinical development. With a focus on addressing key limitations of oncolytic virus therapy—such as immune neutralization and poor tumor penetration—Calidi's technology has potential applicability across multiple solid tumors. The company also has a preclinical pipeline of other oncolytic virus candidates. Despite its innovative approach, Calidi faces typical biotech risks including clinical trial execution, regulatory hurdles, and financing needs. Its small market capitalization and early-stage status imply high reward potential but significant uncertainty.

Upcoming Catalysts (preview)

• Q1 2026Phase I/II data readout for CLD-40135% success
• Q3 2026FDA IND clearance for a second pipeline candidate60% success
• H2 2026Partnership or licensing deal for RedTail platform25% success